Home
OverviewAbout10 LeapsCollaborationImpact
OverviewLeaps TalksChapter FilmsLeaps.orgPartners
AgricultureHealth
OverviewAnnual ReviewBreakthrough StudyPress ReleasesIn the NewsReportsLeaps LeadershipPress KitMedia Contact
Team
  • Approach
    • Overview
    • About
    • 10 Leaps
    • Collaboration
    • Impact
  • Engagement
    • Overview
    • Leaps Talks
    • Chapter Films
    • Leaps.org
    • Partners
    • Agriculture
    • Health
  • News
    • Overview
    • Annual Review
    • Breakthrough Study
    • Press Releases
    • In the News
    • Reports
    • Leaps Leadership
    • Press Kit
    • Media Contact
  • Team
ContactImprintPrivacy StatementConditions of Use
sign up for our newsletter
see more companies

Deka Biosciences

dekabiosciences health logo

Vision

Deka is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases.

Approach

Deka has developed the next generation of cytokine therapy - Diakine™. Diakines™ are purposely engineered therapeutic proteins that are designed to deliver combinations of clinically validated cytokines to diseased tissue.

Deka uses Precision Medicine to identify patients that will benefit from their Diakines™, because not everyone responds to a given cytokine in the same way. They have developed the appropriate assays and discovered the underlying genetic signatures that are responsible for the differential responses to each Diakine™.

Deka is focused on the development of novel cytokine therapies to treat cancer and inflammatory diseases such as Crohn’s, psoriasis, rheumatoid arthritis and sepsis.

Deka Biosciences is addressing

  • Leap 04 / Prevent and cure cancer
  • Leap 06 / Reverse autoimmune diseases and chronic inflammation

CEO:

John Mumm, PhD

Founders:

John Mumm, PhD

Pavel Khrimian

First investment:

October 2021

www.dekabiosciences.com